an incidence of 450,000 new cases and a mortality of 107,000 cancer deaths per year have been estimated for 2018 [1]. Prostate-specific antigen (PSA) remains as the most used biomarker in the detection of early PCa. However, since 2009, PSA usefulness in PCa screening has been ...
Available tests for prostate cancer screening, namely DRE and PSA alone and in combination, were indicated to be effective by 49%, 43% and 68% of respondents respectively, with older GPs significantly more likely to hold these views. The effect of guidelines was mixed. Less than 8% of ...
FP6, FP7 and Horizon 2020 (H2020) over the last two decades. A vast amount of this research financing was dedicated to research on Alzheimer’s disease (AD), breast cancer (BC) and prostate cancer (PC). There is a growing body of evidence that neurodegenerative ...